GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Operating Margin %
中文

Cellectis (Cellectis) Operating Margin %

: -13,336.13% (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Cellectis's Operating Income for the three months ended in Sep. 2023 was $-20.67 Mil. Cellectis's Revenue for the three months ended in Sep. 2023 was $0.16 Mil. Therefore, Cellectis's Operating Margin % for the quarter that ended in Sep. 2023 was -13,336.13%.

Good Sign:

Cellectis SA operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Cellectis's Operating Margin % or its related term are showing as below:

CLLS' s Operating Margin % Range Over the Past 10 Years
Min: -825.44   Med: -354.42   Max: -24.25
Current: -440.3


CLLS's Operating Margin % is ranked worse than
62.63% of 1025 companies
in the Biotechnology industry
Industry Median: -177.8 vs CLLS: -440.30

Cellectis's 5-Year Average Operating Margin % Growth Rate was 10.10% per year.

Cellectis's Operating Income for the three months ended in Sep. 2023 was $-20.67 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-73.53 Mil.


Cellectis Operating Margin % Historical Data

The historical data trend for Cellectis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -825.47 -813.38 -82.87 -341.01 -467.72

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15,541.48 -36.03 -16,856.83 -13,216.76 -13,336.13

Competitive Comparison

For the Biotechnology subindustry, Cellectis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Cellectis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cellectis's Operating Margin % falls into.



Cellectis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cellectis's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-89.666 / 19.171
=-467.72 %

Cellectis's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-20.671 / 0.155
=-13,336.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis  (NAS:CLLS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cellectis Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cellectis's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Pricing of Follow-On Offering

By Stock market mentor Stock market mentor 02-03-2023